Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 21 of 27
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
NCT00827242
Dose-Escalation Study of LY573636-sodium and Liposomal Doxorubicin in Patients With Advanced Solid Tumors
NCT01214668
A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer
NCT00735696
A Study for Patients With Type 2 Diabetes Mellitus
NCT00804986
A Study in the Treatment of Alcohol Dependence.
NCT00805441
A Study in Adult Patients With Major Depressive Disorder
NCT00795821
Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes
NCT00791479
A Safety Study of LY2811376 Single Doses in Healthy Subjects
NCT00838084
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
NCT00762034
A Study in the Treatment of Osteoarthritis Knee Pain
NCT00790790
A Study for the Treatment of Alcohol Dependence
NCT00804570
A Study for Treatment of Pain in Patients With Diabetic Neuropathy.
NCT00785577
Study in Participants With Acute Migraines Headaches
NCT00804973
A Study of LY2584702 in Participants With Advanced Cancer
NCT01394003
Duloxetine for Multiple Sclerosis Pain
NCT00755807
An Efficacy Study of Compound LY2624803 in the Treatment of Patients With Chronic Insomnia
NCT00784875
A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations
NCT00857454
A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
NCT00785928
A Study of LY2228820 in Participants With Advanced Cancer
NCT01393990
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
NCT00762411
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
NCT00744991
A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread
NCT01648764
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
NCT00686959
Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
NCT00716274
A Study for Patient With Chronic Low Back Pain
NCT00767806
Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer
NCT00703326
Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia
NCT00718159
A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.
NCT00734604
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin
NCT00734474
A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer
NCT00728949
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
NCT00683475
Study of Ramucirumab in Ovarian Cancer
NCT00721162
A Study for Patients That Have Been Previously Been Treated in Waldenstrom's Macroglobulinemia or Multiple Myeloma
NCT00718419
A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma
NCT00668148
A Phase 1b Trial in Patients With Renal Cell Cancer
NCT01258348
A Safety Study in Participants With Advanced Solid Tumors
NCT01284335
A Study of LY2541546 in Healthy Postmenopausal Women
NCT01742078
A Study Comparing Duloxetine and Placebo in the Treatment of Fibromyalgia
NCT00673452
A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy
NCT00689728
Fibromyalgia Health Outcome Study on Cost of Treatments
NCT00725101
A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations
NCT00702650
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
NCT00699998
A Study for Patients With Acute Leukemia
NCT01214655
A Dose-Escalation Study for Patients With Advanced Cancer
NCT01214642
A Study Comparing Duloxetine to Other Antidepressants in the Treatment of Severe Depression
NCT00666757
A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus
NCT00630825
Third Optimizing Anti-Platelet Therapy in Diabetes MellitUS (OPTIMUS-3)
NCT00642174
Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock
NCT00604214
Gemcitabine Plus Bevacizumab in Locally Recurrent or Metastatic Breast Cancer
NCT00623233
Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck
NCT00617734
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.